Bristol-Myers's (BMY) Inhibitex (INHX) Takeover Puts Hep-C, Other Biotechs on M&A Watch

Article Stock Quotes (15) Comments (0)

Following Bristol-Myers Squibb's (NYSE: BMY) deal to acquire Hep C drug maker Inhibitex (Nasdaq: INHX) at a 163% premium over the weekend, speculators will be out in force in biotech-land Monday.

First and foremost, speculators will look at remaining Hep C drug developers Achillion Pharmaceuticals (Nasdaq: ACHN) and Idenix Pharmaceuticals (Nasdaq: IDIX). Bigger and more established Hep C player Vertex Pharmaceuticals (Nasdaq: VRTX) could also find itself a target.

Others biotechs said to be takeover targets include:
Alexion Pharmaceuticals (Nasdaq: ALXN), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Dendreon (Nasdaq: DNDN), Human Genome (Nasdaq: HGSI), Incyte Corporation (Nasdaq: INCY), InterMune (Nasdaq: ITMN), Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), Momenta Pharmaceuticals (Nasdaq: MNTA), Seattle Genetics (Nasdaq: SGEN) and ViroPharma Inc. (Nasdaq: VPHM).

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Tesoro Corporation (TSO) May Take Ownership of BP Carson in Early June - Reuters
• Tableau Software (DATA) IPO now indicated $45-$48
• Tableau Software (DATA) IPO Surges Higher

Create E-mail Alert Related Categories

Rumors, Trader Talk

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?